The differences in GNAS and KRAS mutational status and unique pathological behavior observed in the intestinal subtype support the potential driver role of GNAS in histopathological tumor development with unique outcomes that may promote GNAS status as an early prognostic marker itself. Here, KRAS is linked to neoplasm.